Results 21 to 30 of about 58,832 (240)

Evaluation of pleural fluid YKL-40 as a marker of malignant pleural effusion

Egyptian Journal of Chest Disease and Tuberculosis, 2015
The glycoprotein YKL-40 is synthesized both by cancer cells and by tumor-associated macrophages and plays a functional role in tumor progression. Consequently, high serum YKL-40 levels have been associated with a poor prognosis in patients with several ...
Adel Attia, Ayman Rasmy, Amal Amin, Manal Alanazi   +3 more
doaj   +1 more source

Utility of Emerging Novel Criteria “Cancer Ratio” and “Cancer Ratio Plus” in Differentiating Malignant from Nonmalignant Pleural Effusions [PDF]

Indian Journal of Respiratory Care
Background and objectives: Distinguishing between malignant and benign pleural effusion (including tuberculous pleuritis with effusion) is vital for any patient with an exudative pleural effusion.
Humaira Javaid, Rukhsana Akhter, Rumana Makhdoomi, Nazia Walvir, Sumaira Qadiri, Nazia Mahfooz   +5 more
doaj   +1 more source

Cell origins and diagnostic accuracy of interleukin 27 in pleural effusions. [PDF]

PLoS ONE, 2012
The objective of the present study was to investigate the presence of interleukin (IL)-27 in pleural effusions and to evaluate the diagnostic significance of pleural IL-27.
Wei-Bing Yang, Qiu-Li Liang, Zhi-Jian Ye, Chun-Mi Niu, Wan-Li Ma, Xian-Zhi Xiong, Rong-Hui Du, Qiong Zhou, Jian-Chu Zhang, Huan-Zhong Shi   +9 more
doaj   +1 more source

Managing malignant pleural effusion

Cleveland Clinic Journal of Medicine, 2019
Malignant pleural effusion can be managed in different ways, including clinical observation, thoracentesis, placement of an indwelling pleural catheter, and chemical pleurodesis. The optimal strategy depends on a variety of clinical factors. This article uses cases to illustrate the rationale for determining the best approach in different situations.
Ali Saeed, Wahla, Mateen, Uzbeck, Yaser Abu, El Sameed, Zaid, Zoumot   +3 more
openaire   +2 more sources

Malignant pleural mesothelioma with resolution of pleural effusion

Respirology Case Reports, 2023
Key message In malignant pleural mesothelioma patients, pleural effusion may improve during the course of the disease. Pleural effusion with nodular shadows bordering the pleura should be followed up even if the pleural effusion improves.
Sayaka Nishida, Kazutoshi Toriyama, Makiko Yomota, Yukio Hosomi   +3 more
doaj   +1 more source

Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with ADA in Differential Diagnosis of Pleural Exudative Effusion

Emergency Medicine International, 2022
Objective. The aim of the study is to investigate the clinical value of matrix metalloproteinases-3 (MMP-3) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) combined with adenosine deaminase (ADA) in pleural effusion and serum in benign and malignant
Zhiyang Xu, Jun Guan, Jianxin Xu, Jiahua Tu, Jiangdong Cheng   +4 more
doaj   +1 more source

Pleural Effusions in Hematologic Malignancies

Chest, 2004
Nearly all hematologic malignancies can occasionally present with or develop pleural effusions during the clinical course of disease. Among the most common disorders are Hodgkin and non-Hodgkin lymphomas, with a frequency of 20 to 30%, especially if mediastinal involvement is present.
Alexandrakis, MG, Passam, FH, Kyriakou, DS, Bouros, D   +3 more
openaire   +3 more sources

Diagnostic value of procalcitonin in pleural effusion

Egyptian Journal of Chest Disease and Tuberculosis, 2020
Background A wide range of diseases can cause pleural effusion. Its diagnosis and management remain a clinical challenge, bearing a significant cost to both patients and health care system.
Abdelsadek H Al-Aarag, Shuzan A Mohammed, Hoda Y Ibrahim, Osama I Mohammad   +3 more
doaj   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

Advanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang, Qian Shen, Yao Lin, Jing Zhu, Xiaolan Zhu, Rui Huang, Yijia Wu, Feiyang Shen, Qian Li, Guopei Zheng, Zhe Zhang, Qian Chu, Junhao Hu, Jianfeng Shen   +13 more
wiley   +1 more source